Isatuximab Phase 3 trial meets primary endpoint of prolonging progression free survival in patients with relapsed/refractory multiple myeloma
Study evaluated the benefit of isatuximab in combination with standard of care in prolonging progression free survival as compared to standard of care in patients wi...





